Myeloperoxidase and C-reactive protein in patients with cocaine-associated chest pain

Katie O'Conor, Anna Marie Chang, Alan H B Wu, Judd E. Hollander

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background Myeloperoxidase (MPO) and C-reactive protein (CRP) are markers of inflammation and elevated levels have been found in patients with acute coronary syndrome (ACS) unrelated to cocaine. We evaluated the utility of MPO and CRP for diagnosis of ACS and the prediction of 30-day adverse cardiovascular events in patients with cocaine-related chest pain. Methods This is a secondary analysis from a prospective cohort study of ED patients who received evaluation for ACS. Structured data collection at presentation included demographics, chest pain history, laboratory results, and electrocardiographic data. Our primary outcome was diagnosis of ACS at index visit and 30-day adverse events. As a secondary analysis, we provide data on a matched cohort without cocaine use. Results Baseline data and CRP were available for 95 cocaine users; 82 had MPO data also. Patients had a mean age of 46.6 (SD 8.1) years, 90% were black, and 62% were male. Acute coronary syndrome occurred in 7% of cocaine users. With respect to diagnosis of ACS, the area under the curve was poor for both MPO (0.65; 95% confidence interval [CI]: 0.40-0.91) and CRP (0.63; 95% CI: 0.39-0.88). Similar results were found for 30-day events. With respect to prognosis of 30-day adverse cardiovascular events, the area under the curve was 0.68 (95% CI: 0.45-0.91) for MPO and 0.67 (95% CI: 0.45-0.90) for CRP. Similar results were found for 30-day events. In the matched cohort of patients who were not cocaine users, performance of MPO (n = 66) and CRP (n = 86) was also poor. Conclusions Myeloperoxidase and CRP are not useful for diagnosis or prognosis of patients with cocaine-associated chest pain.

Original languageEnglish (US)
Pages (from-to)664-669
Number of pages6
JournalAmerican Journal of Emergency Medicine
Volume31
Issue number4
DOIs
StatePublished - Apr 2013
Externally publishedYes

Fingerprint

Chest Pain
Cocaine
C-Reactive Protein
Peroxidase
Acute Coronary Syndrome
Confidence Intervals
Area Under Curve
Cohort Studies
Demography
Prospective Studies
Inflammation

ASJC Scopus subject areas

  • Emergency Medicine

Cite this

Myeloperoxidase and C-reactive protein in patients with cocaine-associated chest pain. / O'Conor, Katie; Chang, Anna Marie; Wu, Alan H B; Hollander, Judd E.

In: American Journal of Emergency Medicine, Vol. 31, No. 4, 04.2013, p. 664-669.

Research output: Contribution to journalArticle

O'Conor, Katie ; Chang, Anna Marie ; Wu, Alan H B ; Hollander, Judd E. / Myeloperoxidase and C-reactive protein in patients with cocaine-associated chest pain. In: American Journal of Emergency Medicine. 2013 ; Vol. 31, No. 4. pp. 664-669.
@article{f82c341f113e423c87cfb31c52444a34,
title = "Myeloperoxidase and C-reactive protein in patients with cocaine-associated chest pain",
abstract = "Background Myeloperoxidase (MPO) and C-reactive protein (CRP) are markers of inflammation and elevated levels have been found in patients with acute coronary syndrome (ACS) unrelated to cocaine. We evaluated the utility of MPO and CRP for diagnosis of ACS and the prediction of 30-day adverse cardiovascular events in patients with cocaine-related chest pain. Methods This is a secondary analysis from a prospective cohort study of ED patients who received evaluation for ACS. Structured data collection at presentation included demographics, chest pain history, laboratory results, and electrocardiographic data. Our primary outcome was diagnosis of ACS at index visit and 30-day adverse events. As a secondary analysis, we provide data on a matched cohort without cocaine use. Results Baseline data and CRP were available for 95 cocaine users; 82 had MPO data also. Patients had a mean age of 46.6 (SD 8.1) years, 90{\%} were black, and 62{\%} were male. Acute coronary syndrome occurred in 7{\%} of cocaine users. With respect to diagnosis of ACS, the area under the curve was poor for both MPO (0.65; 95{\%} confidence interval [CI]: 0.40-0.91) and CRP (0.63; 95{\%} CI: 0.39-0.88). Similar results were found for 30-day events. With respect to prognosis of 30-day adverse cardiovascular events, the area under the curve was 0.68 (95{\%} CI: 0.45-0.91) for MPO and 0.67 (95{\%} CI: 0.45-0.90) for CRP. Similar results were found for 30-day events. In the matched cohort of patients who were not cocaine users, performance of MPO (n = 66) and CRP (n = 86) was also poor. Conclusions Myeloperoxidase and CRP are not useful for diagnosis or prognosis of patients with cocaine-associated chest pain.",
author = "Katie O'Conor and Chang, {Anna Marie} and Wu, {Alan H B} and Hollander, {Judd E.}",
year = "2013",
month = "4",
doi = "10.1016/j.ajem.2012.11.026",
language = "English (US)",
volume = "31",
pages = "664--669",
journal = "American Journal of Emergency Medicine",
issn = "0735-6757",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Myeloperoxidase and C-reactive protein in patients with cocaine-associated chest pain

AU - O'Conor, Katie

AU - Chang, Anna Marie

AU - Wu, Alan H B

AU - Hollander, Judd E.

PY - 2013/4

Y1 - 2013/4

N2 - Background Myeloperoxidase (MPO) and C-reactive protein (CRP) are markers of inflammation and elevated levels have been found in patients with acute coronary syndrome (ACS) unrelated to cocaine. We evaluated the utility of MPO and CRP for diagnosis of ACS and the prediction of 30-day adverse cardiovascular events in patients with cocaine-related chest pain. Methods This is a secondary analysis from a prospective cohort study of ED patients who received evaluation for ACS. Structured data collection at presentation included demographics, chest pain history, laboratory results, and electrocardiographic data. Our primary outcome was diagnosis of ACS at index visit and 30-day adverse events. As a secondary analysis, we provide data on a matched cohort without cocaine use. Results Baseline data and CRP were available for 95 cocaine users; 82 had MPO data also. Patients had a mean age of 46.6 (SD 8.1) years, 90% were black, and 62% were male. Acute coronary syndrome occurred in 7% of cocaine users. With respect to diagnosis of ACS, the area under the curve was poor for both MPO (0.65; 95% confidence interval [CI]: 0.40-0.91) and CRP (0.63; 95% CI: 0.39-0.88). Similar results were found for 30-day events. With respect to prognosis of 30-day adverse cardiovascular events, the area under the curve was 0.68 (95% CI: 0.45-0.91) for MPO and 0.67 (95% CI: 0.45-0.90) for CRP. Similar results were found for 30-day events. In the matched cohort of patients who were not cocaine users, performance of MPO (n = 66) and CRP (n = 86) was also poor. Conclusions Myeloperoxidase and CRP are not useful for diagnosis or prognosis of patients with cocaine-associated chest pain.

AB - Background Myeloperoxidase (MPO) and C-reactive protein (CRP) are markers of inflammation and elevated levels have been found in patients with acute coronary syndrome (ACS) unrelated to cocaine. We evaluated the utility of MPO and CRP for diagnosis of ACS and the prediction of 30-day adverse cardiovascular events in patients with cocaine-related chest pain. Methods This is a secondary analysis from a prospective cohort study of ED patients who received evaluation for ACS. Structured data collection at presentation included demographics, chest pain history, laboratory results, and electrocardiographic data. Our primary outcome was diagnosis of ACS at index visit and 30-day adverse events. As a secondary analysis, we provide data on a matched cohort without cocaine use. Results Baseline data and CRP were available for 95 cocaine users; 82 had MPO data also. Patients had a mean age of 46.6 (SD 8.1) years, 90% were black, and 62% were male. Acute coronary syndrome occurred in 7% of cocaine users. With respect to diagnosis of ACS, the area under the curve was poor for both MPO (0.65; 95% confidence interval [CI]: 0.40-0.91) and CRP (0.63; 95% CI: 0.39-0.88). Similar results were found for 30-day events. With respect to prognosis of 30-day adverse cardiovascular events, the area under the curve was 0.68 (95% CI: 0.45-0.91) for MPO and 0.67 (95% CI: 0.45-0.90) for CRP. Similar results were found for 30-day events. In the matched cohort of patients who were not cocaine users, performance of MPO (n = 66) and CRP (n = 86) was also poor. Conclusions Myeloperoxidase and CRP are not useful for diagnosis or prognosis of patients with cocaine-associated chest pain.

UR - http://www.scopus.com/inward/record.url?scp=84875421014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875421014&partnerID=8YFLogxK

U2 - 10.1016/j.ajem.2012.11.026

DO - 10.1016/j.ajem.2012.11.026

M3 - Article

VL - 31

SP - 664

EP - 669

JO - American Journal of Emergency Medicine

JF - American Journal of Emergency Medicine

SN - 0735-6757

IS - 4

ER -